![](jpg/gettyimages-1134798557-150x150.jpg)
grail
-
EU Orders Grail Sale; Illumina Continues Appeals But Plans for Multiple Outcomes
European Union regulators ordered Illumina to divest Grail. Illumina is appealing antitrust findings in Europe and the U.S., but the DNA sequencing giant revealed that divesting all or part of Grail is an option even if it wins both legal challenges.
-
Devices & Diagnostics, BioPharma
Europe Imposes Maximum Fine on Illumina for Early Grail Acquisition
Illumina must pay a €432 million fine for closing its Grail acquisition before the European Commission finished its inquiry into the tie-up. The penalty is the maximum amount the regulator can impose on a company for breaching European merger rules.
-
Jorie Healthcare CEO Shares Why Automation is Critical to Revenue Cycle Management
The revenue cycle management business is using AI tools to automate cumbersome tasks to help hospitals operate more efficiently. It’s beginning to attract the attention of major healthcare organizations.
-
Devices & Diagnostics, BioPharma, Legal
FTC Orders Illumina to Divest Grail, Says Deal Stifles Cancer Test Competition
The Federal Trade Commission has ordered Illumina to divest Grail, the liquid biopsy company it acquired for more than $7 billion. The agency said Illumina’s proposed remedies are insufficient and the tie-up is likely to reduce competition in the R&D and commercialization of new cancer tests.
-
Carrum Health, GRAIL strike up partnership to offer cancer test to employers
Through the new collaboration, Carrum Health is offering GRAIL’s cancer test called Galleri as a benefit option for employers. It is an early-detection test for more than 50 types of cancer.
-
StartUPDATES: New developments from healthcare startups
Check out new developments from Memory Health, Carrum Health, Carmine Therapeutics and Alleva.
-
Prepping for FDA approval, Grail is partnering with health systems to validate its pan-cancer test
Grail, a company focused on early cancer detection, introduced its test that screens for more than 50 kinds of cancer last year. At AWS’ Thursday conference for healthcare and life sciences innovation, the company’s chief security officer explained how the company is evaluating the test in clinical trials and preparing to file for its FDA approval.
-
Illumina’s Grail buyout beats deadline, but legal and regulatory hurdles remain
In closing its Grail acquisition before U.S. and European regulators sign off, Illumina is taking a chance the deal will pass regulatory muster. It’s a potentially pricey gambit, as Illumina could face fines for its early action and there are no assurances that regulators will agree that the deal is not anticompetitive.
-
MedCity Influencers, Diagnostics
Would Illumina’s acquisition of GRAIL constrict the expansion of the liquid biopsy space?
The Federal Trade Commission and the European Union are reviewing the soundness of this acquisition. But if Illumina acquires Grail, the company that it spawned back in January 2016, will it squeeze the nascent liquid biopsy market?
-
Illumina’s $7.1B Grail buyout is challenged by FTC on competitive grounds
The Federal Trade Commission is opposing Illumina’s proposed $7.1 billion Grail acquisition, arguing that it will reduce competition for multi-cancer early detection tests. Illumina disagrees with the regulator’s position and will oppose the FTC’s challenge.
-
Navigating Healthcare’s Data Revolution: Priorities, Opportunities, and Challenges for Health Systems
Arcadia recently partnered with HIMSS Market Insights to survey executives, IT, technology, and clinical leaders. Here’s what we found.
-
String of FDA approvals gives momentum to liquid biopsies
Following years of research and investment, liquid biopsies are steadily accumulating FDA approvals. The tests are being used in molecular profiling of solid tumors and as companion diagnostics for targeted cancer therapies.
-
Health IT, Startups, Diagnostics, Health Tech
Funding roundup: GRAIL raises $390M for cancer liquid biopsy test
GRAIL, a startup developing cancer liquid biopsy tests, raised a $390 million series D round. Read more about which companies raised funding this week.
-
Grail validation data show highly accurate detection of cancers, tissues of origin
The company plans to present the validation data, from its Circulating Cell-Free Genome Atlas, at an ASCO conference taking place in Bangkok this weekend.
-
Study finds Guardant’s liquid biopsy adept at detecting biomarker used by Merck immunotherapy drug
The study, by US and Korean researchers, found Guardant360’s detection of MSI-H/dMMR “highly concordant” with that of standard tissue biopsy, including in a subset of gastric cancer patients who responded to immunotherapy.
-
Freenome nabs $160M to advance blood-based colorectal cancer test
The South San Francisco company intends to use the funding to launch its pivotal trial for its blood-based colorectal cancer screening and submit its test for parallel review for CMS coverage.